Cytotoxicity of paclitaxel in biodegradable self-assembled core-shell poly(lactide-co-glycolide ethylene oxide fumarate) nanoparticles

Pharmaceutical Research

Volumn 25, Issue 7, 2008, Pages 1552-1562

  He, Xuezhong ^a   Ma, Junyu ^a   Mercado, Angel E ^a   Xu, Weijie ^a   Jabbari, Esmaiel ^a  

^a University of South Carolina   (United States)

Author keywords

Biodegradable nanoparticle; Core shell morphology; Self assembly; Tumor drug delivery

Indexed keywords

CHLORIDE; FUMARIC ACID DERIVATIVE; FUMARYLCHLORIDE; NANOPARTICLE; PACLITAXEL; POLY(LACTIDE CO ETHYLENE OXIDE FUMARATE); POLY(LACTIDE CO GLYCOLIDE FURAMATE); POLY(LACTIDE FUMARATE); POLYGLACTIN; POLYLACTIDE;

ANIMAL EXPERIMENT; ARTICLE; BIODEGRADABILITY; CELL STRAIN HCT116; CELL VIABILITY; CHEMICAL REACTION; COLON CARCINOMA; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DEGRADATION; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ENCAPSULATION; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; INCUBATION TIME; INFRARED SPECTROMETRY; INTESTINE; MALE; MISCIBILITY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALORIMETRY, DIFFERENTIAL SCANNING; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DIMETHYL SULFOXIDE; DRUG CARRIERS; DRUG COMPOUNDING; HCT116 CELLS; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; SOLUBILITY; SOLVENTS; SPECTROSCOPY, NEAR-INFRARED;

EID: 44749086167     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9513-z     Document Type: Article

References (59)

1. ACS. Cancer Facts & Figures. American Cancer Society, Atlanta, GA, Website: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf, (2007).
2. W. P. McGuire, E. K. Rowinsky, N. B. Rosenshein, F. C. Grumbine, D. S. Ettinger, D. K. Armstrong, and R. C. Donehower. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111:273 (1989).
3. S. Gagandeep, P. M. Novikoff, M. Ott, and S. Gupta. Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. Cancer Res. 136:109 (1999).
4. E. K. Rowinsky, and R. C. Donehower. Paclitaxel (Taxol). N. Engl. J. Med. 332:104 (1995).
5. G. J. MacEachern-Keith, L. J. Wagner, M. J. Butterfield, and I. Mattina. Paclitaxel stability in solution. Anal. Chem. 69:72 (1997).
6. A. K. Singla, A. Garg, and D. Aggarwal. Paclitaxel and its formulations. Int. J. Pharm. 235:179 (2002).
7. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer. 37:1590 (2001).
8. Q. Zhao, B. Han, Z. Wang, C. Gao, C. Peng, and J. Shen. Hollow chitosan-alginate multilayer microcapsules as drug delivery vehicle: doxorubicin loading and in vitro and in vivo studies. Nanomedicine. 3:63 (2007).
9. M. Schmitt-Sody, S. Strieth, S. Krasnici, B. Sauer, B. Schulze, M. Teifel, U. Michaelis, K. Naujoks, and M. Dellian. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin. Cancer Res. 9:2335 (2003).
10. M. Nahar, T. Dutta, S. Murugesan, A. Senthilkumar, A. Asthana, D. Abhay, D. Mishra, V. Rajkumar, M. Tare, S. Saraf, and N. Kumar. Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. Critical Rev. Therap. Drug Carrier Sys. 23:259 (2006).
11. T. Ooya, J. Lee, and K. Park. Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J. Control. Release. 93:121 (2003).
12. J. W. Xie, and C. H. Wang. Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxe. Pharm. Res. 22:2079 (2005).
13. M. Zeisser-Labouebe, N. Lange, R. Gurny, and F. Delie. Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int. J. Pharmaceutics. 326:174 (2006).
14. C. Fonseca, S. Simoes, and R. Gaspar. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Release. 83:273 (2002).
15. S. Modi, J. J. Prakash, A. J. Domb, and N. Kumar. Exploiting EPR in polymer drug conjugate delivery for tumor targeting. Curr. Pharm. Des. 12:4785 (2006).
16. A. K. Iyer, G. Khaled, J. Fang, and H. Maeda. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today. 11:812 (2006).
17. L. H. Reddy. Drug delivery to tumours: recent strategies. J. Pharm. Pharmacol. 57:1231 (2005).
18. S. K. Hobbs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, and R. K. Jain. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A. 95:4607 (1998).
19. S. Unezaki, K. Maruyama, J.-I. Hosoda, I. Nagae, Y. Koyanagi, M. Nakata, O. Ishida, M. Iwatsuru, and S. Tsuchiya. Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int. J. Pharm. 144:11 (1996).
20. O. Gallego, and V. Puntes. Can nanotechnology do to fight cancer? Clin. Transl. Oncol. 8:788 (2006).
21. N. Nishiyama, and K. Kataoka. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 112:630 (2006).
22. C. Vauthier, C. Dubernet, C. Chauvierre, I. Brigger, and P. Couvreur. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control. Release 93:151 (2003).
23. Y. Kato, H. Onishi, and Y. Machida. Application of chitin and chitosan derivatives in the pharmaceutical field. Curr. Pharm. Biotechnol. 4:303 (2003).
24. I. Brigger, C. Dubernet, and P. Couvreur. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54:631 (2002).
25. R. M. Owen, C. B. Carlson, J. Xu, P. Mowery, E. Fasella, and L. L. Kiessling. Bifunctional ligands that target cells displaying the αvβ3 integrin. ChemBioChem. 8:68 (2007).
26. R. Fernandez-Urrusuno, E. Fattal, J. M. Rodrigues, J. Feger, P. Bedossa, and P. Couvreur. Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J. Biomed. Mater. Res. 31:401 (1996).
27. M. Cegnar, J. Kristl, and J. Kos. Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours. Expert Opin. Biol. Ther. 5:1557 (2005).
28. S. Kommareddy, S. B. Tiwari, and M. M. Amiji. Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technol. Cancer Res. Treat. 4:615 (2005).
29. G. Kaul, and M. Amiji. Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. J. Drug Target. 12:585 (2004).
30. C.-H. Heldin, K. Rubin, K. Pietras, and A. Ostman. High interstitial pressure- An obstacle in cancer therapy. Nature Rev. 4:806 (2004).
31. H. Maeda, J. Fang, T. Inutsuka, and Y. Kitamoto. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3:319 (2003).
32. S. N. Ettinger, C. C. Poellmann, N. A. Wisniewski, A. A. Gaskin, J. S. Shoemaker, J. M. Poulson, M. W. Dewhirst, and B. Klitzman. Urea as a recovery marker for quantitative assessment of tumor interstitial solutes with microdialysis. Cancer Res. 61:7964 (2001).
33. E. Jababri, and X. He. Release characteristics of novel bioresorbable in-situ crosslinkable self assembled nanoparticles. CRS Abstract. CS:1 (2007).
34. E. Jabbari, and X. He. Synthesis and characterization of bioresorbable in situ crosslinkable ultra low molecular weight poly(lactide) macromer. J. Mater. Sci. Mater. Med. PMID:17597374 (2007).
35. X. He, and E. Jabbari. Material properties and cytocompatibility of injectable MMP degradable poly(lactide ethylene oxide fumarate) hydrogel as a carrier for marrow stromal cells. Biomacromolecules. 8:780 (2007).
36. A. S. Sarvestani, X. He, and E. Jabbari. The Effect of osteonectin-derived peptide on the viscoelasticity of hydrogel/apatite nanocomposite scaffolds. Biopolymers. 85:370 (2007).
37. E. Jabbari, and X. He. Synthesis and material properties of functionalized lactide oligomers as in situ crosslinkable scaffolds for tissue regeneration. Polym. Prepr. 47:353 (2006).
38. A. S. Sarvestani, X. He, and E. Jabbari. Rheological characterization and modeling of gelation kinetics of injectable in situ crosslinkable poly (lactide-ethylene oxide-fumarate) hydrogels. Biomacromolecules. 8:406 (2007).
39. J. Groden, A. Thliveris, W. Samowitz, M. Carlson, L. Gelbert, H. Albertsen, G. Joslyn, J. Stevens, L. Spirio, and M. Robertson. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 66:589 (1991).
40. A. Sparreboom, J. van Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, and O. van Tellingen. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94:2031 (1997).
41. P. D. Scholes, A. G. Coombes, L. Illum, S. S. Davis, J. F. Watts, C. Ustariz, M. Vert, and M. C. Davies. Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J. Control. Release. 59:261 (1999).
42. L. Mu, and S. S. Feng. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm. Res. 20:1864 (2003).
43. H. B. Ravivarapu, H. Lee, and P. P. DeLuca. Enhancing initial release of peptide from poly(d,llactide-co-glycolide) (PLGA) microspheres by addition of a porosigen and increasing drug load. Pharm. Dev. Technol. 5:287 (2000).
44. A. Messaritaki, S. J. Black, C. F. van der Walle, and S. P. Rigby. NMR and confocal microscopy studies of the mechanisms of burst drug release from PLGA microspheres. J. Control. Release. 108:271 (2005).
45. J. Siepmann, K. Elkharraz, F. Siepmann, and D. Klose. How autocatalysis accelerates drug release from PLGA-based microparticles: a quantitative treatment. Biomacromolecules. 6:2312 (2005).
46. D. Klose, F. Siepmann, K. Elkharraz, S. Krenzlin, and J. Siepmann. How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Int. J. Pharm. 314:198 (2006).
47. E. Jabbari, W. Xu, and X. He. Degradation characteristics of novel in-situ crosslinkable poly(lactide-co-glycolide-ethylene oxide-fumarate) copolymer networks. Trans. Soc. Biomaterials. 1:353 (2007).
48. M. O. Oyewumi, R. A. Yokel, M. Jay, T. Coakley, and R. J. Mumper. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J. Control. Release. 95:613 (2004).
49. M. O. Oyewumi, and R. J. Mumper. Influence of formulation parameters on gadolinium entrapment and tumor cell uptake using folate-coated nanoparticles. Int. J. Pharm. 251:85 (2003).
50. M. Louis, D. Beck, D. Merkle, and G. Ciraolo. Particle size does not affect the rate of intracellular routing for ligands internalized by non-adsorptive pinocytosis. J. Electron Microsc. 46:337 (1997).
51. B. D. Chithrani, A. A. Ghazani, and W. C. Chan. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6:662 (2006).
52. H. L. Wong, R. Bendayan, A. M. Rauth, H. Y. Xue, K. Babakhanian, and X. Y. Wu. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther. 317:1372 (2006).
53. Taxol clinical pharmacology, RxList. http://www.rxlist.com/cgi/generic/ paclitaxel_cp.htm.
54. I. Gut, V. Danielova, J. Holubova, P. Soucek, and H. Kluckova. Cytotoxicity of cyclophosphamide, paclitaxel, and docetaxel for tumor cell lines in vitro: effects of concentration, time and cytochrome P450-catalyzed metabolism. Arch. Toxicol. 74:437 (2000).
55. C. H. Shu, W. K. Yang, Y. L. Shih, M. L. Kuo, and T. S. Huang. Cell cycle G2/M arrest and activation of cyclin-dependent kinases associated with low-dose paclitaxel-induced sub-G1 apoptosis. Apoptosis. 2:463 (1997).
56. T. H. Wang, H. S. Wang, and Y. K. Soong. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 88:2619 (2000).
57. W. P. McGuire. Paclitaxel in cancer treatment. Informa Health Care, Oxon, UK, 1995, p. 7.
58. M. G. Catalano, L. Costantino, N. Fortunati, O. Bosco, M. Pugliese, G. Boccuzzi, L. Berta, and R. Frairia. High energy shock waves activate 5'-aminolevulinic acid and increase permeability to Paclitaxel: antitumor effects of a new combined treatment on anaplastic thyroid cancer cells. Thyroid. 17:91 (2007).
59. M. V. Varma, and R. Panchagnula. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci. 25:445 (2005).